FDG PET/BT’DE ARTMIŞ FDG TUTULUMU GÖSTEREN NADİR BİR ALT EKSTREMİTE YUMUŞAK DOKU SARKOMU: MİKSOİD LİPOSARKOM OLGUSU
Abstract
Sağ
uyluk posteriorunda miksoid liposarkom tanılı 45 yaşında erkek olgunun evreleme
amaçlı [18F]-2-floro-2-deoksi-D-glukoz (FDG) pozitron emisyon tomografisi
(PET)/bilgisayarlı tomografi (BT) görüntülemesi yapılmıştır. Olgunun sağ uyluk
orta ve distal 1/3 kesimi posteriorunda yaklaşık
105x92 mm boyutlarda, lobüle konturlu, komşu adale yapılarını iten, BT’de septalarla ayrılmış miksoid-kistik ve yağ bileşenleri
içeren, füzyon görüntülerde ise heterojen artmış FDG tutulumu gösteren (SUVmaks: 3.35) yumuşak doku kitlesi saptanmıştır.
Diğer FDG PET/BT kesitlerinde metastaz
tespit edilememiş olup, görüntüleme sonrasında
kitle total olarak çıkarılmıştır. FDG PET/BT yumuşak doku sarkomlarında
grade belirlemede kullanılmakta olup, biyopsinin nereden alınacağının
saptanmasında da önemli rol oynamaktadır. FDG PET/BT, alt ekstremitesinde
miksoid liposarkom kitlesi bulunan olgumuzun evrelemesinde, metastaz
değerlendirmesine katkı sağladığı için yararlı bulunmuştur.
References
- 1. Loubignac F, Bourtoul C, Chapel F. (2009). Myxoid liposarcoma: a rare soft-tissue tumor with a misleading benign appearance. World J Surg Oncol; 7:42.
- 2. Nieweg OE, Pruim J, Hoekstra HJ, Paans AM, Vaalburg W, Oldhoff J, Schraffordt Koops H. (1994). Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma. J Nucl Med; 35(1):90–2.
- 3. Hicks RJ. (2005). Functional imaging techniques for evaluation of sarcomas. Cancer Imaging; 5(1):58–65.
- 4. Townsend DW, Beyer T, Blodgett TM. (2003). PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med; 33:193–204.
- 5. Hicks RJ, Toner GC, Choong PF. (2005). Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging; 5(1):66–72.
- 6. Eary JF, O'Sullivan F, Powitan Y, Chandhury KR, Vernon C, Bruckner JD, Conrad EU. (2002). Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging; 29:1149–54.
- 7. Sambri A, Bianchi G, Longhi A, Righi A, Donati DM, Nanni C, Fanti S, Errani C. (2019). The role of 18F-FDG PET/CT in soft tissue sarcoma. Nucl Med Commun; 40(6):626−31.
- 8. Knebel C, Lenze U, Pohlig F, Lenze F, Harrasser N, Suren C, Breitenbach J, Rechl H, Eisenhart-Rothe R, Mühlhofer HML. (2017). Prognostic factors and outcome of liposarcoma patients: a retrospective evaluation over 15 years. BMC Cancer; 17:410.
- 9. Dalal KM, Antonescu CR, Singer S. (2008). Diagnosis and management of lipomatous tumors. J Surg Oncol; 97(4):298–313.
A RARE LOWER EXTREMITY SOFT TISSUE SARCOMA WITH INCREASED FDG UPTAKE ON FDG PET/CT: A CASE OF MYXOID LIPOSARCOMA
Abstract
Abstract
A 45
years old man with the diagnosis of myxoid liposarcoma in posterior part of his
right thigh underwent [18F]-2-fluoro-2-deoxy-D-glucose (FDG) positron
emission tomography (PET)/computed tomography (CT) for staging purpose. In posterior
of the middle and distal 1/3 parts of the right femur, a soft tissue mass
measuring 105x92 mm with lobulated
contours pushing neighboring muscles was detected which included septated
myxoid-cystic and fat components on CT images and showed heterogeneously increased
FDG uptake (SUVmax: 3.35) on FDG-PET/CT fusion images. No evidence of metastasis could be
detected on other FDG PET/CT images and the tumor was removed
totally after imaging. FDG PET/CT is being used for grading purpose in soft
tissue sarcomas and plays important role in determining the site for biopsy. FDG
PET/CT was found to be useful in staging of our case with myxoid liposarcoma
because of its contribution to metastasis evaluation.
References
- 1. Loubignac F, Bourtoul C, Chapel F. (2009). Myxoid liposarcoma: a rare soft-tissue tumor with a misleading benign appearance. World J Surg Oncol; 7:42.
- 2. Nieweg OE, Pruim J, Hoekstra HJ, Paans AM, Vaalburg W, Oldhoff J, Schraffordt Koops H. (1994). Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma. J Nucl Med; 35(1):90–2.
- 3. Hicks RJ. (2005). Functional imaging techniques for evaluation of sarcomas. Cancer Imaging; 5(1):58–65.
- 4. Townsend DW, Beyer T, Blodgett TM. (2003). PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med; 33:193–204.
- 5. Hicks RJ, Toner GC, Choong PF. (2005). Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging; 5(1):66–72.
- 6. Eary JF, O'Sullivan F, Powitan Y, Chandhury KR, Vernon C, Bruckner JD, Conrad EU. (2002). Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging; 29:1149–54.
- 7. Sambri A, Bianchi G, Longhi A, Righi A, Donati DM, Nanni C, Fanti S, Errani C. (2019). The role of 18F-FDG PET/CT in soft tissue sarcoma. Nucl Med Commun; 40(6):626−31.
- 8. Knebel C, Lenze U, Pohlig F, Lenze F, Harrasser N, Suren C, Breitenbach J, Rechl H, Eisenhart-Rothe R, Mühlhofer HML. (2017). Prognostic factors and outcome of liposarcoma patients: a retrospective evaluation over 15 years. BMC Cancer; 17:410.
- 9. Dalal KM, Antonescu CR, Singer S. (2008). Diagnosis and management of lipomatous tumors. J Surg Oncol; 97(4):298–313.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Case Report |
| Authors | |
| Publication Date | December 31, 2019 |
| Published in Issue | Year 2019Volume: 4 Issue: 3 |
